Bioengineered Tumor‐Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance

Abstract Antiangiogenic therapies, such as bevacizumab, are among the causes of cancer‐related death in patients with colorectal cancer (CRC) with liver metastasis. Delivering siRNAs via primary cell originating from primary cells is a promising method for targeting CRC liver metastasis and drug res...

Full description

Saved in:
Bibliographic Details
Main Authors: Junjiang Wang, Chunsheng Liu, Ping Wang, Zhiyuan Liu, Weixian Hu, Zejian Lv, Chengzhi Huang, Xueqing Yao
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Advanced Science
Subjects:
Online Access:https://doi.org/10.1002/advs.202417714
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850208120643518464
author Junjiang Wang
Chunsheng Liu
Ping Wang
Zhiyuan Liu
Weixian Hu
Zejian Lv
Chengzhi Huang
Xueqing Yao
author_facet Junjiang Wang
Chunsheng Liu
Ping Wang
Zhiyuan Liu
Weixian Hu
Zejian Lv
Chengzhi Huang
Xueqing Yao
author_sort Junjiang Wang
collection DOAJ
description Abstract Antiangiogenic therapies, such as bevacizumab, are among the causes of cancer‐related death in patients with colorectal cancer (CRC) with liver metastasis. Delivering siRNAs via primary cell originating from primary cells is a promising method for targeting CRC liver metastasis and drug resistance. Here, it is found that the expression of CCL24 is significantly upregulated in tumor tissues at the CRC liver metastasis site. In addition, CCL24 is significantly upregulated in tumor tissues from bevacizumab‐resistant patients. CCL24 promotes the formation of inflammatory tumor‐associated fibroblast subsets in the CRC liver metastasis microenvironment and induces resistance to bevacizumab therapy. Based on these results, a primary cell‐derived extracellular vehicle delivery system is designed for the simultaneous delivery of siRNAs targeting CCL24 in the tumor microenvironment (TME). Downregulation of CCL24 in the TME by delivering bioengineered extracellular vehicles significantly increased sensitivity to antiangiogenic therapy in a CRC mouse model. A novel therapeutic target is identified for patients with CRC with liver metastasis and suggested a possible therapeutic alternative for patients with CRC with resistance to antiangiogenic therapy and distant metastasis.
format Article
id doaj-art-79d93d4dea2e4e7e954f2f157cf19717
institution OA Journals
issn 2198-3844
language English
publishDate 2025-06-01
publisher Wiley
record_format Article
series Advanced Science
spelling doaj-art-79d93d4dea2e4e7e954f2f157cf197172025-08-20T02:10:19ZengWileyAdvanced Science2198-38442025-06-011223n/an/a10.1002/advs.202417714Bioengineered Tumor‐Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab ResistanceJunjiang Wang0Chunsheng Liu1Ping Wang2Zhiyuan Liu3Weixian Hu4Zejian Lv5Chengzhi Huang6Xueqing Yao7Department of Gastrointestinal Surgery Department of General Surgery Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Southern Medical University Guangzhou 510000 ChinaDepartment of Gastrointestinal Surgery Department of General Surgery Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Southern Medical University Guangzhou 510000 ChinaDepartment of Gastrointestinal Surgery Department of General Surgery Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Southern Medical University Guangzhou 510000 ChinaDepartment of Gastrointestinal Surgery Department of General Surgery Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Southern Medical University Guangzhou 510000 ChinaDepartment of Gastrointestinal Surgery Department of General Surgery Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Southern Medical University Guangzhou 510000 ChinaDepartment of Gastrointestinal Surgery Department of General Surgery Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Southern Medical University Guangzhou 510000 ChinaDepartment of Gastrointestinal Surgery Department of General Surgery Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Southern Medical University Guangzhou 510000 ChinaDepartment of Gastrointestinal Surgery Department of General Surgery Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Southern Medical University Guangzhou 510000 ChinaAbstract Antiangiogenic therapies, such as bevacizumab, are among the causes of cancer‐related death in patients with colorectal cancer (CRC) with liver metastasis. Delivering siRNAs via primary cell originating from primary cells is a promising method for targeting CRC liver metastasis and drug resistance. Here, it is found that the expression of CCL24 is significantly upregulated in tumor tissues at the CRC liver metastasis site. In addition, CCL24 is significantly upregulated in tumor tissues from bevacizumab‐resistant patients. CCL24 promotes the formation of inflammatory tumor‐associated fibroblast subsets in the CRC liver metastasis microenvironment and induces resistance to bevacizumab therapy. Based on these results, a primary cell‐derived extracellular vehicle delivery system is designed for the simultaneous delivery of siRNAs targeting CCL24 in the tumor microenvironment (TME). Downregulation of CCL24 in the TME by delivering bioengineered extracellular vehicles significantly increased sensitivity to antiangiogenic therapy in a CRC mouse model. A novel therapeutic target is identified for patients with CRC with liver metastasis and suggested a possible therapeutic alternative for patients with CRC with resistance to antiangiogenic therapy and distant metastasis.https://doi.org/10.1002/advs.202417714colorectal cancerantiangiogenic therapyengineered extracellular vehiclesliver metastasissiRNA delivery
spellingShingle Junjiang Wang
Chunsheng Liu
Ping Wang
Zhiyuan Liu
Weixian Hu
Zejian Lv
Chengzhi Huang
Xueqing Yao
Bioengineered Tumor‐Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance
Advanced Science
colorectal cancer
antiangiogenic therapy
engineered extracellular vehicles
liver metastasis
siRNA delivery
title Bioengineered Tumor‐Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance
title_full Bioengineered Tumor‐Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance
title_fullStr Bioengineered Tumor‐Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance
title_full_unstemmed Bioengineered Tumor‐Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance
title_short Bioengineered Tumor‐Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance
title_sort bioengineered tumor derived extracellular vehicles suppressed colorectal cancer liver metastasis and bevacizumab resistance
topic colorectal cancer
antiangiogenic therapy
engineered extracellular vehicles
liver metastasis
siRNA delivery
url https://doi.org/10.1002/advs.202417714
work_keys_str_mv AT junjiangwang bioengineeredtumorderivedextracellularvehiclessuppressedcolorectalcancerlivermetastasisandbevacizumabresistance
AT chunshengliu bioengineeredtumorderivedextracellularvehiclessuppressedcolorectalcancerlivermetastasisandbevacizumabresistance
AT pingwang bioengineeredtumorderivedextracellularvehiclessuppressedcolorectalcancerlivermetastasisandbevacizumabresistance
AT zhiyuanliu bioengineeredtumorderivedextracellularvehiclessuppressedcolorectalcancerlivermetastasisandbevacizumabresistance
AT weixianhu bioengineeredtumorderivedextracellularvehiclessuppressedcolorectalcancerlivermetastasisandbevacizumabresistance
AT zejianlv bioengineeredtumorderivedextracellularvehiclessuppressedcolorectalcancerlivermetastasisandbevacizumabresistance
AT chengzhihuang bioengineeredtumorderivedextracellularvehiclessuppressedcolorectalcancerlivermetastasisandbevacizumabresistance
AT xueqingyao bioengineeredtumorderivedextracellularvehiclessuppressedcolorectalcancerlivermetastasisandbevacizumabresistance